Abstract
Gliomas comprise heterogeneous malignant glial and stromal cells. While blood vessel co-option is a potential mechanismto escape anti-angiogenic therapy, the relevance of glial phenotype in this process is unclear. We show that Olig2(+) oligodendrocyte precursor-like glioma cells invade by single-cell vessel co-option and preserve the blood-brain barrier (BBB). Conversely, Olig2-negative glioma cells form dense perivascular collections and promote angiogenesis and BBB breakdown, leading to innate immune cell activation. Experimentally, Olig2 promotes Wnt7b expression, a finding that correlates in human glioma profiling. Targeted Wnt7a/7b deletion or pharmacologic Wnt inhibition blocks Olig2(+) glioma single-cell vessel co-option and enhances responses to temozolomide. Finally, Olig2 and Wnt7 become upregulated after anti-VEGF treatment in preclinical models and patients. Thus, glial-encoded pathways regulate distinct glioma-vascular micro-environmental interactions.
| Original language | English |
|---|---|
| Pages (from-to) | 874-889 |
| Number of pages | 23 |
| Journal | Cancer Cell |
| Volume | 33 |
| Issue number | 5 |
| DOIs | |
| State | Published - 14 May 2018 |
All Science Journal Classification (ASJC) codes
- Oncology
- Cancer Research